If the FDA is happy with daprodustat's safety profile and approves the drug, it will help GSK meet its target of £500 million to £1 billion ($650 million to $1.3 billion) in sales for the drug ...
GSK may have been hoping to get through the review for daprodustat without the FDA calling on its expert advisors, but it will now have to make the case for the safety and efficacy of its drug at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback